Back to top
more

Bristol Myers Squibb (BMY)

(Delayed Data from NYSE)

$42.98 USD

42.98
17,140,067

+0.31 (0.73%)

Updated Jul 23, 2024 04:00 PM ET

After-Market: $42.98 0.00 (0.00%) 4:18 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth F Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (82 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

New York-based Bristol-Myers Squibb is a one of the leading global specialty bio-pharmaceutical companies focused on the development of treatments targeting serious diseases. Backed by its blockbuster immune-oncology drug, Opdivo, Bristol-Myers has a strong oncology portfolio, consisting of other drugs like Revlimid, Sprycel, Yervoy and Empliciti. Beyond oncology, the company has important immunology and cardiovascular drugs like Orencia and Eliquis, which diversify its portfolio. Notably, in the cardiovascular space, Eliquis is now the global leading oral anti-coagulant drug. The company continues to experience growth in both the Eliquis brand and the market, while also advancing its Factor XIa inhibitor program..

Bristol Myers Squibb (BMY) Gains But Lags Market: What You Should Know

by Zacks Equity Research

Bristol Myers Squibb (BMY) closed the most recent trading day at $78.89, moving +0.08% from the previous trading session.

The Zacks Analyst Blog Highlights Merck, Bristol-Myers Squibb and Deere

by Zacks Equity Research

Merck, Bristol-Myers Squibb and Deere are included in this Analyst Blog.

Exelixis (EXEL) Reports Data from CONTACT-01, QUARTZ-101 Study

by Zacks Equity Research

Exelixis (EXEL) announces that the phase III study, CONTACT-01, did not meet its primary endpoint. It also releases initial data from the QUARTZ-101 study.

Sheraz Mian headshot

Early Q4 Earnings Results and Analyst Reports for Merck, Bristol-Myers & Deere

by Sheraz Mian

Today's Research Daily features update on the Q4 earnings season and new research reports on Merck (MRK), Bristol-Myers (BMY) and Deere (DE).

Bristol Myers Squibb (BMY) is a Top-Ranked Value Stock: Should You Buy?

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Mirati (MRTX) Down After 1st-Line Lung Cancer Data on Adagrasib

by Zacks Equity Research

Mirati Therapeutics' (MRTX) preliminary data from the first-line NSCLC study showed that adagrasib plus Merck's Keytruda achieved an objective response rate of 49%.

Alkermes (ALKS) Up 4.4% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Alkermes (ALKS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Investors Heavily Search Bristol Myers Squibb Company (BMY): Here is What You Need to Know

by Zacks Equity Research

Zacks.com users have recently been watching Bristol Myers (BMY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Blueprint Medicines (BPMC) Up 3.7% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Blueprint Medicines (BPMC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

bluebird (BLUE) to Boost Cash With Priority Review Voucher Sale

by Zacks Equity Research

bluebird (BLUE) is set to sell one of its two priority review vouchers. This will strengthen its financial position as its existing cash balance is expected to exhaust by second-quarter 2023.

Why Is Bristol Myers (BMY) Up 6.3% Since Last Earnings Report?

by Zacks Equity Research

Bristol Myers (BMY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Mirati's (MRTX) Stock Rallies 11% on Buyout Speculations

by Zacks Equity Research

Mirati Therapeutics' (MRTX) new drug application (NDA), seeking approval for adagrasib, its KRAS inhibitor drug, for previously-treated KRASG12C-mutated NSCLC is under review with the FDA with a decision expected by Dec 14.

Merck (MRK) Keytruda Advanced Gastric Cancer Study Meets Goal

by Zacks Equity Research

Top-line data from a late-stage study shows that Merck's (MRK) Keytruda combined with chemotherapy improved overall survival in patients with advanced gastric cancer.

Prothena (PRTA) Earns Milestone Payment From Novo Nordisk

by Zacks Equity Research

Prothena (PRTA) earns a $40 million milestone payment from Novo Nordisk following the progress of NNC6019 in a phase II study for the treatment of ATTR cardiomyopathy.

Bristol Myers (BMY) Gains 24.2% YTD: What's in Store for 2023?

by Zacks Equity Research

Biotech giant Bristol Myers (BMY) outperforms the industry and the S&P 500 Index as Eliquis and Opdivo maintain momentum despite generic competition for Revlimid.

Iovance (IOVA) Extends Timeline for Rolling BLA of Melanoma Drug

by Zacks Equity Research

Post FDA's feedback on lifileucel, Iovance (IOVA) extends its timeline to complete the rolling BLA submission for lifileucel in melanoma. It expects to complete the filing in the first quarter.

Mirati's (MRTX) Stock Rises on Q3 Earnings and Sales Beat

by Zacks Equity Research

Mirati Therapeutics (MRTX) reports narrower-than-expected Q3 loss. Revenues also beat the mark. Stock rises in after-hours trading.

The Zacks Analyst Blog Highlights Berkshire Bristol-Myers Squibb, Verizon Communications, Canadian National Railway, Airbnb and First Republic Bank

by Zacks Equity Research

Berkshire Bristol-Myers Squibb, Verizon Communications, Canadian National Railway, Airbnb and First Republic Bank are included in this Analyst Blog.

Sheraz Mian headshot

Top Analyst Reports for Bristol-Myers, Verizon & Canadian National Railway

by Sheraz Mian

Today's Research Daily features new research reports on 16 major stocks, including Berkshire Bristol-Myers Squibb Company (BMY), Verizon Communications Inc. (VZ) and Canadian National Railway Company (CNI).

Nektar's (NKTR) Q3 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Nektar (NKTR) reports encouraging third-quarter 2022 results. The narrower-than-expected loss is on account of lower operating expenses incurred during the quarter.

Iovance's (IOVA) Q3 Earnings Beat Estimates, Revenues Nil

by Zacks Equity Research

Iovance Biotherapeutics (IOVA) reports a wider-than-expected loss in Q3. The company is on track to initiate a rolling BLA submission for lifileucel in melanoma later this month.

Prothena's (PRTA) Q3 Earnings Miss, Revenues Decline Y/Y

by Zacks Equity Research

Prothena (PRTA) incurs a loss in the third quarter while revenues miss estimates.

Exelixis (EXEL) Q3 Earnings & Sales Top, Cabometyx Aids Growth

by Zacks Equity Research

Exelixis (EXEL) tops earnings and sales estimates for the third quarter as demand for its lead drug, Cabometyx, remains strong.

How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings

by Zacks Equity Research

Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.

Pfizer (PFE) Beats on Q3 Earnings, Ups COVID Jab Sales View

by Zacks Equity Research

Pfizer (PFE) beats estimates for Q3 earnings and sales. It ups its sales and earnings view despite a decline in COVID-19 vaccine sales in Q3. Stock up in pre-market trading